ICU Medical, Inc. (ICUI)

ICU Medical's stock has experienced a decline over the past six months. Key events impacting the stock include the Q4 2025 earnings announcement, where revenue beat estimates but declined year-over-year, raising demand concerns. The Q3 2025 earnings announcement showed a decrease in revenue but an increase in adjusted diluted EPS and adjusted EBITDA. Pacific Capital Partners Ltd significantly reduced its stake in ICU Medical. A shareholder investigation was launched into potential director fiduciary duty breaches. Vanguard's SEC filing reported 0% ownership due to an internal structural realignment. Geopolitical tensions have also weighed on the stock.

Recent performance indicates that demand for ICU Medical's products has slowed, with revenue remaining flat over the last two years. Analysts anticipate a further decline in revenue by 3.4% over the next 12 months, suggesting ongoing demand challenges. The disposal of its IV Solutions business on May 1, 2025, also impacted revenue.

ICU Medical, Inc. is a medical technology company focused on developing, manufacturing, and selling medical products for infusion therapy, vascular access, and vital care applications. Their product portfolio includes infusion therapy products, oncology products, vital care products, and pharmacy compounding systems. The company serves acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities globally.

ICU Medical, Inc. is headquartered in San Clemente, California, and has a significant international presence. As of December 31, 2024, the company had approximately 15,000 employees in over 35 countries. Its key geographic markets include the U.S., Europe, Asia-Pacific, the Middle East and Africa, and other foreign countries.

ICU Medical was recognized by Forbes Magazine in 2014 as one of the "100 Most Trustworthy Companies in America". The shareholder investigation launched by Purcell & Lefkowitz LLP into potential director fiduciary duty breaches could negatively impact the company's reputation.

Institutional investors dominate the ownership of ICU Medical, Inc., holding approximately 87.03% of the shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, Janus Henderson Group Plc, and State Street Corp. Executives and directors collectively hold a low-single-digit percentage stake.